Strides Plans Injectables Re-entry As Mylan Non-Compete Nears End

 
• By Vibha Ravi

Indian firm Strides to invest up to $40m in acquired Stelis for re-entry into generic injectables and multiple biosimilar APIs as it looks to build its business.  

ine conveyor for labeling and packaging ampoules in boxes
Strides Moves Back Into Injectables • Source: Shutterstock

More from Business

More from Scrip